Precision
medicine
envisages
the
integration
of
an
individual’s
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual's
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Journal of Medical Internet Research,
Journal Year:
2024,
Volume and Issue:
26, P. e49230 - e49230
Published: May 13, 2024
Pharmacogenetics
can
impact
patient
care
and
outcomes
through
personalizing
the
selection
of
medicines,
resulting
in
improved
efficacy
a
reduction
harmful
side
effects.
Despite
existence
compelling
clinical
evidence
international
guidelines
highlighting
benefits
pharmacogenetics
practice,
implementation
within
National
Health
Service
United
Kingdom
is
limited.
An
important
barrier
to
overcome
development
IT
solutions
that
support
integration
pharmacogenetic
data
into
health
systems.
This
necessitates
better
understanding
role
electronic
records
(EHRs)
design
decision
systems
are
acceptable
clinicians,
particularly
those
primary
care.
Clinical and Translational Science,
Journal Year:
2024,
Volume and Issue:
17(6)
Published: June 1, 2024
Abstract
Pharmacogenetic
testing
could
reduce
the
time
to
identify
a
safe
and
effective
medication
for
depression;
however,
it
is
underutilized
in
practice.
Major
depression
constitutes
most
common
mental
disorder
US,
while
antidepressant
therapy
can
help,
current
trial
–and
error
approach
require
patients
endure
multiple
trials
before
finding
one
that
effective.
Tailoring
fit
of
pharmacogenetic
with
prescribers'
needs
across
variety
settings
help
establish
generalizable
value
proposition
improve
likelihood
adoption.
We
conducted
study
explore
health
systems
using
medications
through
real‐world
experiences
implementation
science
concepts
systematic
interviews
prescribers
administrators
from
four
care
systems.
To
proposition,
we
organized
themes
according
Triple
Aim
framework,
leading
framework
policy
which
asserts
high‐value
should
focus
on
three
key
metrics:
(1)
better
quality
(2)
population‐level
outcomes
(3)
reduced
per
capita
costs.
Primary
providers
whom
interviewed
said
they
because
would
provide
more
information
about
prescribe,
expanding
their
ability
best‐fit
reducing
reliance
referrals
specialists;
this
capacity
meet
patients'
access
primary
care.
At
same
time,
expressed
differing
views
how
whether
out‐of‐pocket
cost
prevent
them
offering
it.
Thus,
integrating
into
strategies
support
interactions
patients.
Genes,
Journal Year:
2024,
Volume and Issue:
15(7), P. 862 - 862
Published: July 1, 2024
There
is
growing
evidence
that
pharmacogenetic
analysis
can
improve
drug
therapy
for
individual
patients.
In
Switzerland,
pharmacists
are
legally
authorized
to
initiate
tests.
However,
tests
rarely
conducted
in
Swiss
pharmacies.
Therefore,
we
aimed
identify
implementation
strategies
facilitate
the
integration
of
a
pharmacist-led
service
into
clinical
practice.
To
achieve
this,
semi-structured
interviews
with
and
physicians
regarding
process
service.
We
utilized
Consolidated
Framework
Implementation
Research
(CFIR)
potential
facilitators
barriers
process.
Additionally,
employed
Expert
Recommendations
Implementing
Change
(ERIC)
mentioned
used
CFIR-ERIC
matching
tool
additional
strategies.
obtained
interview
responses
from
nine
physicians.
From
these
responses,
identified
7
CFIR
constructs
as
12
barriers.
Some
most
commonly
included
unclear
procedures,
lack
cost
coverage
by
health
care
insurance,
insufficient
pharmacogenetics
knowledge,
interprofessional
collaboration,
communication
patient,
inadequate
e-health
technologies.
23
interviewees
using
ERIC
45
tool.
summary,
found
significant
hinder
this
new
hope
highlighting
strategies,
advance
Switzerland.
Clinical Pharmacology & Therapeutics,
Journal Year:
2023,
Volume and Issue:
114(2), P. 262 - 265
Published: May 4, 2023
Aminoglycoside
antibiotic
exposure
can
result
in
ototoxicity
and
irreversible
hearing
loss
among
individuals
that
harbor
the
m.1555A>G
variant
mitochondrial
12S
rRNA
gene,
MT-RNR1.
Importantly,
pre-emptive
screening
has
been
shown
to
reduce
prevalence
of
pediatric
aminoglycoside-induced
ototoxicity;
however,
professional
guidelines
support
guide
post-test
pharmacogenomic
counseling
this
context
are
not
currently
available.
This
Perspective
highlights
key
issues
with
delivering
MT-RNR1
results,
including
longitudinal
familial
care
considerations
communicating
heteroplasmy.
Drug and Therapeutics Bulletin,
Journal Year:
2023,
Volume and Issue:
61(11), P. 168 - 172
Published: Oct. 3, 2023
There
is
considerable
interindividual
variability
in
the
effectiveness
and
safety
of
medicines.
Although
reasons
for
this
are
multifactorial,
it
well
recognised
that
genetic
changes
impacting
absorption
or
metabolism
these
drugs
play
a
significant
contributory
role.
Understanding
how
pharmacogenetic
variants
impact
response
to
medicines,
leveraging
knowledge
guide
prescribing,
could
have
benefits
patients
health
services.
This
article
provides
an
introduction
field
pharmacogenetics,
including
its
nomenclature,
existing
evidence
base
current
state
implementation
globally.
We
discuss
challenges
translating
research
into
clinical
practice
highlight
which
can
emerge
those
services
where
successful.
British Journal of Clinical Pharmacology,
Journal Year:
2024,
Volume and Issue:
90(7), P. 1699 - 1710
Published: April 14, 2024
Genetic
testing
can
be
used
to
improve
the
safety
and
effectiveness
of
commonly
prescribed
medicines-a
concept
known
as
pharmacogenetics.
This
study
aimed
quantify
members
UK
public's
preferences
for
a
pharmacogenetic
service
delivered
in
primary
care
National
Health
Service.
Pharmacy,
Journal Year:
2023,
Volume and Issue:
11(2), P. 76 - 76
Published: April 17, 2023
The
use
of
pharmacogenetics
to
optimize
pharmacotherapy
is
growing
rapidly.
This
study
evaluates
the
feasibility
and
operability
a
collaborative
circuit
involving
hospital
community
pharmacists
implement
clopidogrel
in
Barcelona,
Catalonia,
Spain.
We
aimed
enroll
patients
with
prescription
from
cardiologists
at
collaborating
hospital.
Community
collected
patients'
pharmacotherapeutic
profiles
saliva
samples,
which
were
then
sent
for
CYP2C19
genotyping.
Hospital
collated
obtained
data
clinical
records.
Data
analyzed
jointly
cardiologist
assess
suitability
clopidogrel.
provincial
pharmacists'
association
coordinated
project
provided
IT
logistic
support.
began
January
2020.
However,
it
was
suspended
March
2020
due
COVID-19
pandemic.
At
that
moment,
120
had
been
assessed,
16
whom
met
inclusion
criteria
enrolled
study.
processing
samples
before
pandemic
an
average
delay
13.8
±
5.4
days.
A
total
37.5%
intermediate
metabolizers
18.8%
ultrarapid
metabolizers.
No
poor
detected.
Pharmacists
rated
their
experience
7.3
2.7
likelihood
recommending
fellow
participate.
net
promoter
score
among
participating
+10%.
Our
results
show
feasible
operable
further
initiatives.
Journal of Personalized Medicine,
Journal Year:
2022,
Volume and Issue:
12(11), P. 1821 - 1821
Published: Nov. 2, 2022
PGx
testing
requires
a
complex
set
of
activities
undertaken
by
practitioners
and
patients,
resulting
in
varying
implementation
success.
This
systematic
review
aimed
(PROSPERO:
CRD42019150940)
to
identify
barriers
enablers
patients
implementing
pharmacogenomic
testing.
We
followed
PRISMA
guidelines
conduct
report
this
review.
Medline,
EMBASE,
CINAHL,
PsycINFO,
PubMed
Central
were
systematically
searched
from
inception
June
2022.
The
theoretical
domain
framework
(TDF)
guided
the
organisation
reporting
or
relating
activities.
From
twenty-five
eligible
reports,
eleven
described
four
stages:
ordering,
facilitating,
interpreting,
applying
Four
themes
identified
across
IT
infrastructure,
effort,
rewards,
unknown
territory.
Barriers
most
consistently
mapped
TDF
domains:
memory,
attention
decision-making
processes,
environmental
context
resources,
belief
about
consequences.
